PMID- 37669131
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20231216
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 41
IP  - 1
DP  - 2024 Jan
TI  - Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes 
      mellitus: An open-label, non-randomized pilot study.
PG  - e15217
LID - 10.1111/dme.15217 [doi]
AB  - INTRODUCTION: The role of dapagliflozin on erectile dysfunction (ED), a condition 
      widely affecting patients with type 2 diabetes mellitus (T2DM), has not yet been 
      studied. AIM: The aim of the study was to evaluate the effects of dapagliflozin 
      alone or in combination with tadalafil on ED in patients with T2DM. METHODS: This 
      was an open-label, non-randomized pilot study involving 30 Caucasian male 
      patients with T2DM and severe ED. They were equally divided into three groups, 
      assigned to treatment with tadalafil 5 mg/day (Group 1), tadalafil 5 mg/day plus 
      dapagliflozin 10 mg/day (Group 2) and dapagliflozin 10 mg/day (Group 3) for 3 
      months. The presence and the severity of ED were evaluated at enrolment and after 
      treatment, by the International Index of Erectile Function 5-item (IIEF-5) 
      questionnaire and the dynamic penile echo colour Doppler ultrasound (PCDU) 
      examination. RESULTS: At the end of treatment, the three groups showed a 
      significant improvement in IIEF-5 score, by 294%, 375% and 197%, in Groups 1, 2 
      and 3, respectively. PCDU evaluation showed a significant increase in peak 
      systolic velocity by 178.9%, 339% and 153%; acceleration time was significantly 
      shortened in Group 2 (-26.2%) and was significantly lower than in Group 1 and 3 
      (-7.2% and -6.6%), while no significant difference was found in end-diastolic 
      velocity after treatment. The greatest rates of improvement were observed in 
      Group 2 for all the end points. CONCLUSIONS: Dapagliflozin improves ED in 
      patients with T2DM and enhances the efficacy of tadalafil. Further studies are 
      needed to confirm our results explain the mechanism(s) by which dapagliflozin 
      exerts its effects on ED.
CI  - (c) 2023 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on 
      behalf of Diabetes UK.
FAU - Cannarella, Rossella
AU  - Cannarella R
AUID- ORCID: 0000-0003-4599-8487
AD  - Department of Clinical and Experimental Medicine, University of Catania, Catania, 
      Italy.
AD  - Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Cleveland, 
      Ohio, USA.
FAU - Condorelli, Rosita A
AU  - Condorelli RA
AD  - Department of Clinical and Experimental Medicine, University of Catania, Catania, 
      Italy.
FAU - Leanza, Claudia
AU  - Leanza C
AD  - Department of Clinical and Experimental Medicine, University of Catania, Catania, 
      Italy.
FAU - Garofalo, Vincenzo
AU  - Garofalo V
AD  - Department of Clinical and Experimental Medicine, University of Catania, Catania, 
      Italy.
FAU - Aversa, Antonio
AU  - Aversa A
AD  - Department of Experimental and Clinical Medicine, Magna Graecia University of 
      Catanzaro, Catanzaro, Italy.
FAU - Papa, Giuseppe
AU  - Papa G
AD  - Unit of Metabolic and Endocrine Disease, Centro Catanese di Medicina e Chirurgia 
      Clinic, Catania, Italy.
FAU - Calogero, Aldo E
AU  - Calogero AE
AD  - Department of Clinical and Experimental Medicine, University of Catania, Catania, 
      Italy.
FAU - La Vignera, Sandro
AU  - La Vignera S
AD  - Department of Clinical and Experimental Medicine, University of Catania, Catania, 
      Italy.
LA  - eng
GR  - N/A/None/
PT  - Journal Article
DEP - 20230915
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
RN  - 742SXX0ICT (Tadalafil)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 0 (Carbolines)
SB  - IM
MH  - Humans
MH  - Male
MH  - *Erectile Dysfunction/drug therapy/etiology
MH  - Tadalafil/therapeutic use
MH  - Pilot Projects
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Carbolines
MH  - Treatment Outcome
OTO - NOTNLM
OT  - SGLT2i
OT  - T2DM
OT  - dapagliflozin
OT  - erectile dysfunction
OT  - tadalafil
EDAT- 2023/09/05 18:42
MHDA- 2023/12/17 09:42
CRDT- 2023/09/05 12:23
PHST- 2023/08/09 00:00 [revised]
PHST- 2023/06/15 00:00 [received]
PHST- 2023/08/28 00:00 [accepted]
PHST- 2023/12/17 09:42 [medline]
PHST- 2023/09/05 18:42 [pubmed]
PHST- 2023/09/05 12:23 [entrez]
AID - 10.1111/dme.15217 [doi]
PST - ppublish
SO  - Diabet Med. 2024 Jan;41(1):e15217. doi: 10.1111/dme.15217. Epub 2023 Sep 15.